Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › HARBOR-1 (HRS-7535-303, NCT06904105)

HARBOR-1 (HRS-7535-303, NCT06904105)

HRS-7535 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
HRS-7535
Population
obesity
Official title
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Phase
3
Registry status
completed · 2025-04 → 2026-04
Participants
556
Duration
44 weeks
Registry
NCT06904105

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
120 mgobesity china44556−9.5 % vs −2.5 %
Δ −7.0 pp
−8.0 % vs −2.4 %
Δ −5.6 pp
—4.1 vs 2.7—70.3 vs 16.266.7 vs 4.5——press release
180 mgobesity china44556−10.9 % vs −2.5 %
Δ −8.4 pp
−9.8 % vs −2.4 %
Δ −7.4 pp
—3.1 vs 2.7—70.0 vs 16.268.6 vs 4.5——press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (10)
  • 120 mg · weight_tp · press release
    Based on the treatment policy estimand^2, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 8.0% and 9.8% from baseline at Week 44, respectively, compared to 2.4% with placebo.
  • 120 mg · nausea · press release
    nausea (70.3% and 70.0% vs. 16.2% with placebo)
  • 120 mg · vomiting · press release
    vomiting (66.7% and 68.6% vs. 4.5% with placebo)
  • 120 mg · ae_dc · press release
    Treatment discontinuation rates due to TEAEs were 4.1% (120 mg) and 3.1% (180 mg) for HRS-7535 vs. 2.7% with placebo.
  • 120 mg · weight_eff · press release
    Based on the efficacy estimand^1, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 9.5% and 10.9% from baseline at Week 44, respectively, compared to 2.5% with placebo.
  • 180 mg · weight_tp · press release
    Based on the treatment policy estimand^2, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 8.0% and 9.8% from baseline at Week 44, respectively, compared to 2.4% with placebo.
  • 180 mg · nausea · press release
    nausea (70.3% and 70.0% vs. 16.2% with placebo)
  • 180 mg · vomiting · press release
    vomiting (66.7% and 68.6% vs. 4.5% with placebo)
  • 180 mg · ae_dc · press release
    Treatment discontinuation rates due to TEAEs were 4.1% (120 mg) and 3.1% (180 mg) for HRS-7535 vs. 2.7% with placebo.
  • 180 mg · weight_eff · press release
    Based on the efficacy estimand^1, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 9.5% and 10.9% from baseline at Week 44, respectively, compared to 2.5% with placebo.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HARBOR-1 (HRS-7535-303, NCT06904105). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/harbor-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.